American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

At the ASCO 2024 Annual Meeting, researchers summarized the most recent results from the phase 2 study of IMM01 in combination with azacitidine, a first-line treatment for adults with higher-risk myelodysplastic syndromes. Read More ›

Wrap-Up

Efficacy of Luspatercept for the Treatment of Transfusion-Dependent, Erythropoiesis-Stimulating Agent–Naïve Patients With Very Low-, Low-, or Intermediate-Risk MDS in the COMMANDS Trial

ASCO 2024 - Wrap Up: Myelodysplastic Syndrome

At the 2024 ASCO Annual Meeting, researchers’ data from the COMMANDS trial, which evaluated the effectiveness of luspatercept in treating patients with transfusion-dependent, erythropoiesis-stimulating agent–naïve individuals with very low-, low-, or intermediate-risk myelodysplastic syndromes. Read More ›

Anti-HER2/HER3 αDC1 Vaccines Plus Pembrolizumab for Brain Metastasis in Triple-Negative or HER2-Positive BC

ASCO 2023 - Breast Cancer

An ongoing phase 2 study is evaluating HER2/HER3-directed  dendritic cell vaccines combined with pembrolizumab in patients with brain metastasis from triple-negative breast cancer or HER2-positive breast cancer. Read More ›

Neoadjuvant Intratumoral Dendritic Cell Vaccine Therapy Plus Paclitaxel, Trastuzumab, and Pertuzumab in HER2-Positive BC

ASCO 2023 - Breast Cancer

Preliminary results of the phase 2 NATASHA trial showed that neoadjuvant HER2-directed intratumoral dendritic cell vaccine therapy followed by paclitaxel, trastuzumab, and pertuzumab was well-tolerated in patients with HER2-positive breast cancer. Read More ›

Phase 1b/2 Trial of Ribociclib, Tucatinib, and Trastuzumab for HER2-Positive BC

ASCO 2023 - Breast Cancer

The phase 1b/2 UCLA B-13 trial is evaluating the safety and efficacy of HER2 tyrosine kinase inhibitor tucatinib plus the cyclin-dependent kinase 4/6 inhibitor ribociclib and trastuzumab in the neoadjuvant setting for the treatment of patients with HER2-positive breast cancer. Read More ›

Dalpiciclib Combined With Pyrotinib and Endocrine Therapy in Dual Receptor–Positive (ER-Positive/HER2-Positive) MBC

ASCO 2023 - Breast Cancer

Results of the phase 2 PLEASURABLE study indicated that the chemotherapy-sparing regimen of dalpiciclib combined with pyrotinib and endocrine therapy showed significant antitumor activity for patients with estrogen receptor–positive/HER2-positive metastatic breast cancer in the front-line setting. Read More ›

Preclinical and Early Clinical Data of the HER2 Inhibitor ZN-1041 in Patients With BC With Brain Metastases

ASCO 2023 - Breast Cancer

Promising safety and antitumor activity data were obtained with the HER2 inhibitor ZN-1041, which is specifically designed to cross the blood-brain barrier, in preclinical and phase 1 studies in patients with HER2-positive breast cancer with brain metastases. Read More ›

First-Line Zanidatamab Plus Docetaxel in Advanced HER2-Positive BC

ASCO 2023 - Breast Cancer

Updated results of a phase 1b/2 trial showed that zanidatamab plus docetaxel as first-line therapy had a manageable safety profile and demonstrated promising antitumor activity in patients with advanced HER2-positive breast cancer. Read More ›

Real-World Treatment Patterns of Tucatinib Therapy in HER2-Positive MBC

ASCO 2023 - Breast Cancer

Real-world data from a US claims database reported similar efficacy as from a previous clinical trial in patients with previously treated HER2-positive metastatic breast cancer. Read More ›

Anti-HER2 Antibody Inetetamab Plus Camrelizumab and Utidelone for Pretreated HER2-Positive MBC

ASCO 2023 - Breast Cancer

Final results of the phase 2 ICU trial confirmed earlier reports of promising efficacy and acceptable safety of anti-HER2 antibody inetetamab in combination with camrelizumab and utidelone in patients with pretreated HER2-positive metastatic breast cancer. Read More ›

American Society of Clinical Oncology (ASCO)

Page 4 of 33